13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
63 檔
58.7%
At the close of Q3 2024, EcoR1 Capital, LLC disclosed equity holdings valued at approximately $2.1B, spread across 63 reported holdings.
In Q3 2024, EcoR1 Capital, LLC displayed an active expansion posture, initiating 14 new positions and adding to 7 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, ANAB, CRNX) accounted for 58.7% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 11.74% | — | +2.44% | |
| 2 | ANAB | Anaptysbio Inc | Stock-Other | 8.94% | +7.31% | +3.64% | |
| 3 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 7.50% | -6.61% | EXIT | |
| 4 | PRTA | Prothena Corporation plc | Stock-Other | 6.63% | — | — | |
| 5 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 6.51% | -13.69% | EXIT | |
| 6 | ZYME | Zymeworks Inc | Stock-Other | 5.77% | +4.78% | — | |
| 7 | ARVN | Arvinas Inc | Stock-Other | 5.67% | — | — | |
| 8 | KURA | Kura Oncology Inc | Stock-Other | 3.88% | — | — | |
| 9 | XNCR | Xencor Inc | Stock-Other | 3.67% | -1.12% | EXIT | |
| 10 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.51% | — | — | |
| 11 | JANX | Janux Therapeutics Inc | Stock-Other | 2.29% | — | — | |
| 12 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 2.23% | +0.88% | — | |
| 13 | IMNM | Immunome Inc | Stock-Other | 1.94% | — | — | |
| 14 | NGNE | Neurogene Inc | Stock-Other | 1.83% | +0.85% | — | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.76% | -10.81% | EXIT | |
| 16 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.53% | — | — | |
| 17 | NUVB | Nuvation Bio Inc | Stock-Other | 1.51% | — | — | |
| 18 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.48% | — | — | |
| 19 | PCVX | Vaxcyte Inc | Stock-Other | 1.38% | — | +17.49% | |
| 20 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.25% | — | — | |
| 21 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.20% | -0.08% | — | |
| 22 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.19% | — | — | |
| 23 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 24 | MBX | Mbx Biosciences Inc | Stock-Other | 1.05% | +0.06% | — | |
| 25 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.94% | — | — | |
| 26 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.93% | — | — | |
| 27 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.89% | — | — | |
| 28 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.88% | — | — | |
| 29 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.85% | — | — | |
| 30 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 31 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 32 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.70% | — | — | |
| 33 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.69% | — | — | |
| 34 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.68% | — | +30.12% | |
| 35 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.62% | — | — | |
| 36 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.61% | -0.17% | — | |
| 37 | PHVS | Pharvaris N.V. | Stock-Other | 0.57% | +0.40% | NEW | |
| 38 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.56% | — | -50.50% | |
| 39 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.54% | — | — | |
| 40 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.41% | — | — | |
| 41 | KROS | Keros Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 42 | REPL | Replimune Group Inc | Stock-Other | 0.32% | -0.32% | EXIT | |
| 43 | ✓ | Stock-Other | 0.31% | — | — | ||
| 44 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.28% | — | -71.57% | |
| 45 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 46 | GBIOGBX | Generation Bio Co | Stock-Other | 0.17% | — | — | |
| 47 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 0.16% | +1.55% | — | |
| 48 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.15% | +0.31% | -97.31% | |
| 49 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.15% | — | — | |
| 50 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.13% | +0.85% | +15.31% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | JAZZ | Jazz Pharmaceuticals plc | +3.2% | +68.30% | Add |
| 2 | ANAB | Anaptysbio Inc | +3.2% | +3.64% | Add |
| 3 | ZYME | Zymeworks Inc | +2.3% | — | Unchanged |
| 4 | CRNX | Crinetics Pharmaceuticals In | +1.8% | +3.19% | Add |
| 5 | VRDN | Viridian Therapeutics Inc | +1.5% | NEW | New buy |
| 6 | MBX | Mbx Biosciences Inc | +1.1% | NEW | New buy |
| 7 | IONS | Ionis Pharmaceuticals Inc | +0.7% | NEW | New buy |
| 8 | PCVX | Vaxcyte Inc | +0.7% | +17.49% | Add |
| 9 | RLAY | Relay Therapeutics Inc | +0.6% | NEW | New buy |
| 10 | XNCR | Xencor Inc | +0.6% | — | Unchanged |
| 11 | IMNM | Immunome Inc | +0.5% | — | Unchanged |
| 12 | ORIC | Oric Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 13 | TECX | Tectonic Therapeutic Inc | +0.5% | — | Unchanged |
| 14 | EWTX | Edgewise Therapeutics Inc | +0.5% | — | Unchanged |
| 15 | DAWNGBX | Day One Biopharmaceuticals I | +0.4% | NEW | New buy |
| 16 | NGNE | Neurogene Inc | +0.4% | — | Unchanged |
| 17 | JANX | Janux Therapeutics Inc | +0.4% | — | Unchanged |
| 18 | NMRA | Neumora Therapeutics Inc | +0.3% | — | Unchanged |
| 19 | RNAGBP | Avidity Biosciences Inc | +0.2% | — | Unchanged |
| 20 | KURA | Kura Oncology Inc | +0.2% | — | Unchanged |
| 21 | DYN | Dyne Therapeutics Inc | +0.2% | +30.12% | Add |
| 22 | ✓ | Third Harmonic Bio Inc | +0.2% | — | Unchanged |
| 23 | ARVN | Arvinas Inc | +0.2% | — | Unchanged |
| 24 | CRGX | Cargo Therapeutics Inc | +0.2% | — | Unchanged |
| 25 | 260 | Centessa Pharmaceuticals-adr | +0.2% | -43.58% | Trim |
| 26 | ETON | Eton Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 27 | BBIO | Bridgebio Pharma Inc | +0.2% | NEW | New buy |
| 28 | BCYC | Bicycle Therapeutics Plc-adr | +0.1% | — | Unchanged |
| 29 | WHWK | Whitehawk Therapeutics Inc | +0.1% | NEW | New buy |
| 30 | KROS | Keros Therapeutics Inc | +0.1% | — | Unchanged |
| 31 | REPL | Replimune Group Inc | +0.1% | — | Unchanged |
| 32 | ✓ | +0.1% | NEW | New buy | |
| 33 | ALGS | Aligos Therapeutics Inc | +0.1% | NEW | New buy |
| 34 | ADAPY | Adaptimmune Therapeutics-adr | +0.1% | — | Unchanged |
| 35 | AVIR | Atea Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 36 | ✓ | Mersana Therapeutics Inc | +0.1% | — | Unchanged |
| 37 | ✓ | +0.1% | — | Unchanged | |
| 38 | PHVS | Pharvaris N.V. | +0.1% | — | Unchanged |
| 39 | CLDX | Celldex Therapeutics Inc | 0% | — | Unchanged |
| 40 | ARTV | Artiva Biotherapeutics Inc | 0% | NEW | New buy |
| 41 | ATRA | Atara Biotherapeutics Inc | 0% | +15.31% | Add |
| 42 | ✓ | Verve Therapeutics Inc | 0% | — | Unchanged |
| 43 | TNGX | Tango Therapeutics Inc | 0% | — | Unchanged |
| 44 | DSGN | Design Therapeutics Inc | 0% | NEW | New buy |
| 45 | MGNX | Macrogenics Inc | 0% | NEW | New buy |
| 46 | SRZNW | Surrozen Inc-cw25 | 0% | — | Unchanged |
| 47 | ✓ | Proqr Therapeutics N.v. | 0% | -10.12% | Trim |
| 48 | ALLKGUSD | Allakos Inc | — | NEW | New buy |
| 49 | ✓ | — | — | Unchanged | |
| 50 | GBIOGBX | Generation Bio Co | 0% | — | Unchanged |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 63 disclosed positions in Q3 2024.
During Q3 2024, EcoR1 Capital, LLC's top holdings by market value included APLSUSD (11.7%)、ANAB (8.9%)、CRNX (7.5%). The largest single position, APLSUSD, represented 11.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
VRDN
市值: $44.6M
Top Position Liquidated / Trimmed
SRPT
前期市值: $222.4M
In Q3 2024, EcoR1 Capital, LLC made 32 total portfolio adjustments, initiating 14 new buys, adding to 7 positions, trimming 5 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.